Amgen's SWOT analysis: stock outlook amid obesity drug race, pipeline progress
Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...
The American Journal of Managed Care1d
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...
rheumatologyadvisor1d
Nipocalimab Gets Priority Review for Generalized Myasthenia Gravis
The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.
H.C. Wainwright maintains $45 target on Cartesian stock
H.C. Wainwright reaffirmed a Buy rating on Cartesian Therapeutics shares, maintaining the $45.00 price target, representing a ...
PharmaTimes2d
Cartesian Therapeutics announces FDA agreement for new trial
Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol ...
Buy Rating for Cartesian Therapeutics: Promising Phase 3 Prospects for Descartes-08 in Treating Myasthenia Gravis
Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis
This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...
The American Journal of Managed Care6d
Exacerbations Drive Costs, Utilization in Myasthenia Gravis
For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...